• LAST PRICE
    1.9000
  • TODAY'S CHANGE (%)
    0.0000 (0.0000%)
  • Bid / Lots
    1.8700/ 4
  • Ask / Lots
    2.1400/ 25
  • Open / Previous Close
    0.0000 / 1.9000
  • Day Range
    ---
  • 52 Week Range
    Low 1.5200
    High 4.2100
  • Volume
    ---
    below average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
CompanyCountrySymbol
Select an index
Price Comparison Graph. See accessible table below
1 Day Comparison Chart Accessibility Table. Wednesday's close: 1.97
TimeVolumeEYEN
09:32 ET7202.0399
09:35 ET1182.0027
09:42 ET36001.98
09:50 ET1001.98
09:53 ET146701.98
09:55 ET8001.97
10:18 ET86251.97
10:20 ET134291.95
10:22 ET63371.9201
10:24 ET8001.93
10:56 ET1001.93
11:00 ET15001.9281
11:18 ET6181.955
12:21 ET1001.97
12:26 ET1001.97
12:42 ET5321.96
12:51 ET1001.97
01:18 ET1001.94
01:26 ET6231.96
01:38 ET2001.94
01:45 ET37201.93
01:56 ET1001.93
02:09 ET9301.93
02:16 ET12001.94
02:39 ET3001.95
02:41 ET1001.96
02:45 ET1001.96
03:08 ET22981.9406
03:15 ET1001.95
03:30 ET3371.93
03:35 ET17271.9301
03:53 ET9001.93
03:55 ET25251.9
03:57 ET7501.9
04:00 ET15221.9
Data delayed at least 15 minutes.
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
United StatesEYEN
Eyenovia Inc
68.6M
-3.4x
---
United StatesSCYX
SCYNEXIS Inc
69.2M
-1.0x
---
United StatesUG
United-Guardian Inc
51.3M
17.1x
+12.54%
United StatesHOOK
HOOKIPA Pharma Inc
54.4M
-0.6x
---
United StatesRPID
Rapid Micro Biosystems Inc
68.0M
-1.2x
---
United StatesGLS
Gelesis Holdings Inc
25.2M
0.0x
---
As of 2022-12-02

Company Information

Eyenovia, Inc. is a clinical-stage ophthalmic company. The Company is developing a pipeline of therapeutics based on its microdose array print (MAP) platform technology. Its pipeline is focused on the late-stage development of therapeutic indications for pediatric patients with progressive myopia in the United States and patients with age-related near vision impairment, or presbyopia indications. The Company is also developing the microdose fixed combination ophthalmic pharmaceutical for mydriasis. The Company's product candidates include MicroLine (for presbyopia), MicroPine (for progressive myopia) and Mydcombi (for mydriasis). MicroLine is its microdosed version of pilocarpine, an ophthalmic medication that can dose-dependently induce miosis, or a contraction of the pupil. MicroPine is a topical treatment for progressive myopia, a back-of-the-eye disease. Mydcombi is a fixed combination micro-formulation product candidate for mydriasis (eye dilation).

Contact Information

Headquarters
295 Madison Ave Ste 2400NEW YORK, NY, United States 10017
Phone
813-766-9539
Fax
302-636-5454

Executives

Chairman of the Board, Chief Executive Officer, Chief Medical Officer
Tsontcho Ianchulev
Chief Executive Officer, Chief Operating Officer, Director
Michael Rowe
Chief Financial Officer, Secretary
John Gandolfo
Vice President - Clinical Operations
Jennifer Clasby
Vice President - Research & Development and Manufacturing
Luke Clauson

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
$68.6M
Revenue (TTM)
$10.0M
Shares Outstanding
36.1M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
1.57
EPS
$-0.56
Book Value
$0.72
P/E Ratio
-3.4x
Price/Sales (TTM)
6.9
Price/Cash Flow (TTM)
---
Operating Margin
-184.26%
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.